Welcome to our dedicated page for Thermo Fishr Sci news (Ticker: TMO), a resource for investors and traders seeking the latest updates and insights on Thermo Fishr Sci stock.
Thermo Fisher Scientific reports news across scientific instruments, laboratory equipment, diagnostics consumables, life science reagents and pharmaceutical services. Company updates commonly cover operating results, earnings calls, investor presentations and capital deployment through dividends, share repurchases and acquisitions.
Recurring developments also include collaborations tied to laboratory technologies, proteomics, biobank research, analytical instruments and biopharma customer services. Thermo Fisher’s brand portfolio includes Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD, and its completed Clario acquisition added endpoint data solutions for clinical trials to its Laboratory Products and Biopharma Services segment.
Thermo Fisher Scientific (NYSE: TMO) announced a quarterly cash dividend of $0.22 per common share, payable on October 15, 2020, to shareholders of record as of September 15, 2020. The company reported annual revenue exceeding $25 billion and aims to enable healthier, cleaner, and safer environments through innovative technologies and services. With a global workforce of over 75,000, Thermo Fisher delivers industry-leading solutions across various sectors, including life sciences and diagnostics.
Thermo Fisher Scientific (TMO) estimates approximately 10% revenue growth for Q2 2020, driven by strong global sales of PCR-based tests and COVID-19 response products, generating over $1.4 billion in revenue. The company will announce its Q2 financial results on July 22, 2020, followed by a conference call at 8:30 a.m. ET. With annual revenue exceeding $25 billion, Thermo Fisher is committed to advancing health and safety globally.